BR0116169A - Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto. - Google Patents
Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.Info
- Publication number
- BR0116169A BR0116169A BR0116169-5A BR0116169A BR0116169A BR 0116169 A BR0116169 A BR 0116169A BR 0116169 A BR0116169 A BR 0116169A BR 0116169 A BR0116169 A BR 0116169A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- type
- diabetes
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- -1 Isoindolin-1-one-substituted propionamide Chemical class 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA QUE COMPREENDE ESSE COMPOSTO, PROCESSO PARA A PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA, UTILIZAçãO DOS COMPOSTOS, PROCESSO PARA O TRATAMENTO PROFILáTICO OU TERAPêUTICO DE DIABETES DO TIPO II E PROCESSO PARA A PREPARAçãO DO COMPOSTO". Expõem-se estimuladores de glicoquinase de propionamida isoindolin-1-ona-substituída, os quais aumentam a secreção de insulina no tratamento de diabetes do tipo II.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25527300P | 2000-12-13 | 2000-12-13 | |
| US31871501P | 2001-09-13 | 2001-09-13 | |
| PCT/EP2001/014404 WO2002048106A2 (en) | 2000-12-13 | 2001-12-07 | Isoindolin-1-one glucokinase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0116169A true BR0116169A (pt) | 2003-12-23 |
Family
ID=26944583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0116169-5A BR0116169A (pt) | 2000-12-13 | 2001-12-07 | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto. |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6482951B2 (pt) |
| EP (1) | EP1349856B1 (pt) |
| JP (1) | JP4021766B2 (pt) |
| KR (1) | KR100520651B1 (pt) |
| CN (1) | CN1247574C (pt) |
| AT (1) | ATE297922T1 (pt) |
| AU (2) | AU2002238415B2 (pt) |
| BG (1) | BG107903A (pt) |
| BR (1) | BR0116169A (pt) |
| CA (1) | CA2430579C (pt) |
| CY (1) | CY1105587T1 (pt) |
| CZ (1) | CZ20031882A3 (pt) |
| DE (1) | DE60111570T2 (pt) |
| DK (1) | DK1349856T3 (pt) |
| EG (1) | EG24358A (pt) |
| ES (1) | ES2243578T3 (pt) |
| HR (1) | HRP20030450B1 (pt) |
| HU (1) | HUP0400587A3 (pt) |
| IL (2) | IL156264A0 (pt) |
| MA (1) | MA26973A1 (pt) |
| MX (1) | MXPA03005170A (pt) |
| MY (1) | MY136741A (pt) |
| NO (1) | NO325810B1 (pt) |
| NZ (1) | NZ526236A (pt) |
| PA (1) | PA8534601A1 (pt) |
| PE (1) | PE20020593A1 (pt) |
| PL (1) | PL366006A1 (pt) |
| PT (1) | PT1349856E (pt) |
| RS (1) | RS50933B (pt) |
| RU (1) | RU2249590C2 (pt) |
| SI (1) | SI1349856T1 (pt) |
| SK (1) | SK8732003A3 (pt) |
| TW (1) | TWI294876B (pt) |
| UY (1) | UY27069A1 (pt) |
| WO (1) | WO2002048106A2 (pt) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| JP2006509774A (ja) | 2002-10-03 | 2006-03-23 | ノバルティス アクチエンゲゼルシャフト | ２型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換（チアゾール−２−イル）−アミドまたはスルホンアミド |
| ATE374768T1 (de) | 2002-10-03 | 2007-10-15 | Hoffmann La Roche | Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| AU2003294376A1 (en) * | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Heteroaryl compounds |
| EP1594863A1 (en) * | 2003-02-11 | 2005-11-16 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| BRPI0509543A (pt) * | 2004-04-02 | 2007-09-18 | Novartis Ag | derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase |
| BRPI0509573A (pt) | 2004-04-02 | 2007-09-25 | Novartis Ag | derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2 |
| JP4651714B2 (ja) | 2005-07-09 | 2011-03-16 | アストラゼネカ アクチボラグ | 糖尿病の治療においてｇｌｋ活性化剤として使用するためのヘテロアリールベンズアミド誘導体 |
| RU2008112184A (ru) * | 2005-08-31 | 2009-10-10 | Астеллас Фарма Инк. (Jp) | Производное тиазола |
| JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| RU2008112198A (ru) | 2005-09-29 | 2009-10-10 | Санофи-Авентис (Fr) | Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств |
| GT200600429A (es) * | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| CA2627813A1 (en) | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted pyrrolones as allosteric modulators of glucokinase |
| WO2007053503A1 (en) * | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted dihydroisoindolones as allosteric modulators of glucokinase |
| EP1960386A2 (en) * | 2005-11-01 | 2008-08-27 | Janssen Pharmaceutica N.V. | Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase |
| US7531671B2 (en) | 2005-11-01 | 2009-05-12 | Janssen Pharmaceutica N.V. | Dihydroisoindolones as allosteric modulators of glucokinase |
| BRPI0618062A2 (pt) * | 2005-11-03 | 2011-08-16 | Prosidion Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto |
| JP2009515997A (ja) * | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
| US8034822B2 (en) | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US8008332B2 (en) * | 2006-05-31 | 2011-08-30 | Takeda San Diego, Inc. | Substituted indazoles as glucokinase activators |
| WO2008074694A1 (en) * | 2006-12-20 | 2008-06-26 | F. Hoffmann-La Roche Ag | Crystallization of glucokinase activators |
| JP5419706B2 (ja) * | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| JP5248477B2 (ja) * | 2007-03-07 | 2013-07-31 | 杏林製薬株式会社 | グルコキナーゼ活性化物質 |
| WO2008116107A2 (en) * | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
| PE20091313A1 (es) * | 2008-01-15 | 2009-09-03 | Lilly Co Eli | (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina |
| MX2010007926A (es) * | 2008-01-24 | 2010-08-09 | Merck Patent Gmbh | Derivados de beta-aminoacidos. |
| CN105315224B (zh) | 2008-04-28 | 2018-04-10 | 杏林制药株式会社 | 环戊基丙烯酰胺衍生物 |
| CL2009001203A1 (es) | 2008-05-16 | 2009-10-23 | Takeda San Diego Inc | Compuestos derivados de indazol y pirazol sustituidos; composicion farmaceutica de dichos compuestos; kit farmaceutico; y su uso como activadores de la glucoquinasa para tratar enfermedades metabolicas tales como hiperglicemia, diabetes, dislipidemias, obesidad, sindrome metabolico x y enfermedades cardiovasculares. |
| AP2011005613A0 (en) * | 2008-09-11 | 2011-04-30 | Pfizer | Heteroaryls amide derivatives and their use as glucokinase activators. |
| AU2011235212B2 (en) | 2010-03-31 | 2014-07-31 | The Scripps Research Institute | Reprogramming cells |
| US8178689B2 (en) * | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| KR102034748B1 (ko) | 2011-03-01 | 2019-10-21 | 시너지 파마슈티컬즈 인코포레이티드 | 구아닐레이트 사이클라제 c 작용제의 제조 방법 |
| US8470866B2 (en) * | 2011-05-03 | 2013-06-25 | Hoffmann-La Roche Inc. | Isoindolinone derivatives |
| HUE046739T2 (hu) * | 2013-05-27 | 2020-03-30 | Hoffmann La Roche | Új 3,4-dihidro-2H-izokinolin-1-on és 2,3-dihidro-izoindol-1-on vegyületek |
| AU2014274812B2 (en) | 2013-06-05 | 2018-09-27 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
| DK3186242T3 (da) | 2014-08-29 | 2021-12-20 | Tes Pharma S R L | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere |
| AR109950A1 (es) | 2016-10-14 | 2019-02-06 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
| BR112021009589A2 (pt) | 2018-11-20 | 2021-08-17 | Tes Pharma S.R.L. | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
| CN116283717B (zh) * | 2023-01-06 | 2025-04-08 | 暨南大学 | 一种藁本内酯衍生物及其制备方法和应用 |
| WO2024229228A2 (en) * | 2023-05-02 | 2024-11-07 | The Rockefeller University | 1-oxoisoindolin-2-yl amide activators of vcp and derivatives thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2687147A1 (fr) * | 1992-02-11 | 1993-08-13 | Union Pharma Scient Appl | Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| CA2224062C (en) * | 1995-06-06 | 2001-09-04 | Pfizer Limited | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
| HUP0200396A3 (en) | 1999-03-29 | 2003-04-28 | Hoffmann La Roche | Gluckokinase activators, process for their preparation, pharmaceutical compositions containing them and their use |
| EP1280801B1 (en) | 2000-05-03 | 2005-09-07 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
| EP1282611B1 (en) | 2000-05-08 | 2004-10-20 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
-
2001
- 2001-12-06 US US10/010,978 patent/US6482951B2/en not_active Expired - Fee Related
- 2001-12-07 AU AU2002238415A patent/AU2002238415B2/en not_active Ceased
- 2001-12-07 IL IL15626401A patent/IL156264A0/xx unknown
- 2001-12-07 PL PL01366006A patent/PL366006A1/xx unknown
- 2001-12-07 KR KR10-2003-7007869A patent/KR100520651B1/ko not_active Expired - Fee Related
- 2001-12-07 DE DE60111570T patent/DE60111570T2/de not_active Expired - Lifetime
- 2001-12-07 MX MXPA03005170A patent/MXPA03005170A/es active IP Right Grant
- 2001-12-07 DK DK01986857T patent/DK1349856T3/da active
- 2001-12-07 PT PT01986857T patent/PT1349856E/pt unknown
- 2001-12-07 BR BR0116169-5A patent/BR0116169A/pt not_active Application Discontinuation
- 2001-12-07 WO PCT/EP2001/014404 patent/WO2002048106A2/en not_active Ceased
- 2001-12-07 CN CNB018206107A patent/CN1247574C/zh not_active Expired - Fee Related
- 2001-12-07 AU AU3841502A patent/AU3841502A/xx active Pending
- 2001-12-07 CZ CZ20031882A patent/CZ20031882A3/cs unknown
- 2001-12-07 EP EP01986857A patent/EP1349856B1/en not_active Expired - Lifetime
- 2001-12-07 JP JP2002549637A patent/JP4021766B2/ja not_active Expired - Fee Related
- 2001-12-07 SK SK873-2003A patent/SK8732003A3/sk unknown
- 2001-12-07 RU RU2003120512/04A patent/RU2249590C2/ru not_active IP Right Cessation
- 2001-12-07 SI SI200130381T patent/SI1349856T1/xx unknown
- 2001-12-07 AT AT01986857T patent/ATE297922T1/de active
- 2001-12-07 HR HR20030450A patent/HRP20030450B1/xx not_active IP Right Cessation
- 2001-12-07 ES ES01986857T patent/ES2243578T3/es not_active Expired - Lifetime
- 2001-12-07 CA CA2430579A patent/CA2430579C/en not_active Expired - Fee Related
- 2001-12-07 HU HU0400587A patent/HUP0400587A3/hu unknown
- 2001-12-07 NZ NZ526236A patent/NZ526236A/xx unknown
- 2001-12-07 RS YUP-477/03A patent/RS50933B/sr unknown
- 2001-12-10 EG EG20011316A patent/EG24358A/xx active
- 2001-12-10 TW TW090130510A patent/TWI294876B/zh not_active IP Right Cessation
- 2001-12-10 PA PA20018534601A patent/PA8534601A1/es unknown
- 2001-12-11 MY MYPI20015613A patent/MY136741A/en unknown
- 2001-12-11 PE PE2001001234A patent/PE20020593A1/es not_active Application Discontinuation
- 2001-12-12 UY UY27069A patent/UY27069A1/es not_active Application Discontinuation
-
2003
- 2003-06-02 IL IL156264A patent/IL156264A/en not_active IP Right Cessation
- 2003-06-12 MA MA27197A patent/MA26973A1/fr unknown
- 2003-06-12 NO NO20032674A patent/NO325810B1/no not_active IP Right Cessation
- 2003-06-13 BG BG107903A patent/BG107903A/bg unknown
-
2005
- 2005-09-15 CY CY20051101133T patent/CY1105587T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0116169A (pt) | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto. | |
| BR0110573A (pt) | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto | |
| BR0309546A (pt) | Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii | |
| BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
| ATE316786T1 (de) | Behandlung von mukositis | |
| BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| BR0213540A (pt) | Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos | |
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| BR0110492A (pt) | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto | |
| MXPA02006679A (es) | Composicion farmaceutica. | |
| BR0315047A (pt) | Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto | |
| BR9911488A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| BR9710452A (pt) | Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos | |
| EA200000759A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| DE58901401D1 (de) | Pharmazeutische zubereitung zur behandlung des diabetes mellitus. | |
| BR0103736A (pt) | Uso de uma composição que compreende pelo menos um composto metalo-orgânico e processo de tratamento das matérias queratìnicas | |
| ATE344022T1 (de) | Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe | |
| BR0318278A (pt) | compostos de éter aminocicloexìlico e usos dos mesmo | |
| BR9908510A (pt) | Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
| BR0013353A (pt) | Combinação de substância ativa com clonidina | |
| BR0208688A (pt) | Lipìdeo diminuindo bifenil carboxamidas | |
| BRPI0015939B8 (pt) | sistema terapêutico transdérmico com estabilidade aperfeiçoada e processo para a sua preparação | |
| MY134167A (en) | Biphenylcarboxamides useful as lipid lowering agents | |
| BR9913718A (pt) | Processo e composição farmacêutica ou veterinária para inibição profilática ou terapêutica de um material ou substância tóxica em um paciente animal humano ou não-humano, e, uso de um dendrìmero aniÈnico ou catiÈnico | |
| BR9809234A (pt) | Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O ART. 8O COMBINADO COM ART. 13, ART. 10 E ART. 25 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |